trial

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

NCTId NCT01929889
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 19 (actual)
Sponsored by Northwestern University
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
19 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-04
Primary completion
2014-02
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Iloperidone

Sponsors

Northwestern UniversityLead Sponsor
Novartis PharmaceuticalsCollaborator

Investigators

1
John G Csernansky, MDPrincipal Investigator

Sites

1 total
Chicago, United States

Facts & assertions

4 sourced
Enrollment
19
Phase
PHASE4
Primary Completion Date
2014-02
Status
TERMINATED
relationships
The graph out of here
drug
Iloperidone
drug
lead_sponsor
Northwestern University
company
collaborator
Novartis Pharmaceuticals
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
John G Csernansky, MD
person